Alumis

Late-breaker P3 data of our investigational TYK2i at #AAD2026 reinforced its potential as a leading oral therapy for psoriasis. Investor webcast 3/29 at 5pm MDT. bit.ly/EnvuAAD

Today we reported year-end 2025 financial results and a summary of recent achievements and upcoming milestones for envudeucitinib in plaque psoriasis and lupus: bit.ly/4bzoTwp

Envudeucitinib Phase 3 results were accepted for a late‑breaking oral at #AAD2026 on March 28. Investor webcast to follow March 29 at 5pm MDT / 7pm EDT. bit.ly/4rGhMZ3

Hear CEO Martin Babler discuss how Alumis leverages its genomic and genetic insights to design targeted medicines for immune‑mediated diseases. #AutoimmuneAwarenessMonth

Alumis CEO will join a fireside chat at the Leerink Partners Global Healthcare Conference on 3/9. Save the date and watch the live webcast or replay: lnkd.in/eFWyJx-J

Just announced: we’ll join Guggenheim’s Emerging Outlook: Biotech Summit 2026 and Oppenheimer’s 36th Annual Healthcare Life Sciences Conference in February. bit.ly/4km51AM

Excited to head to Maui after our positive Phase 3 data for envudeucitinib. If you’re at Winter Clinical or Maui Derm, stop by our tabletop—we’d love to connect.

We’ve successfully closed our public offering, raising ~$345M to advance our next‑gen targeted therapies for immune‑mediated diseases. bit.ly/4qDHUDM

Positive P3 data announced today for envudeucitinib in plaque psoriasis. All endpoints met. Read our release and join the webcast at 8am EST to learn more. bit.ly/49aBMgt

Tomorrow, Alumis is hosting a conference call and webcast to share topline Phase 3 ONWARD results for envudeucitinib in plaque psoriasis. bit.ly/4jp1xgx

Today, we reported our Q3 2025 financial results and provided highlights of recent progress. Learn more: bit.ly/47HKjGQ

In NYC at the Inflammatory Skin Disease Summit, sharing a new biomarker analysis on envudeucitinib - our investigational treatment for moderate to severe PsO - on November 13.

Today, we announced our participation in two upcoming investor conferences in November. Learn more: bit.ly/47n5UUT

At Fall Clinical Dermatology Conference, we’re sharing a new STRIDE and 52-week OLE analysis for envudeucitinib, focusing on treat-to-target thresholds. Visit our poster!

Alumis will be attending #ACR25 – excited to learn more about where the rheumatology field is headed and how we can help shape it. See you there!

52-week Phase 2 OLE data for envudeucitinib in PsO are now published in the Journal of the American Academy of Dermatology (JAAD). Read the full manuscript: bit.ly/4q6wxob

We're in Orlando this week for a poster presentation at the ASOPRS Fall Symposium and to attend #AAO2025, joining colleagues to advance research in eye health and patient care.

We’re proud to be part of the dialogue shaping the future of MS care at #ECTRIMS2025. If you missed our P1 data poster on A-005, check it out here: bit.ly/42Fjq3m

Alumis is heading to Paris for #EADVCongress, Sept 17–21—joining global experts to drive progress for patients. #EADVCongress